Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver.
Nonalcoholic fatty liver disease (NAFLD) is characterized by high levels of nonesterified fatty acids (NEFA), inflammation, and hepatic steatosis. Inflammation plays a crucial role in the development of fatty liver. Resveratrol (RSV) supplement could improve inflammatory response and hepatic steatosis, whereas the underlying mechanism was not well understood. In this study, mice fed with high-fat diet (HFD) exhibited severe hepatic injury and high blood concentrations of the inflammatory cytokines TNF-α, IL-6, and IL-1β. Hepatic NF-κB inflammatory pathway was over-induced in HFD mice. In vitro, NEFA treatment further increased NF-κB pathway activation in mice hepatocytes, which then promoted the synthesis of inflammatory cytokines. Interestingly, RSV treatment significantly inhibited overactivation of NF-κB pathway and improved hepatic steatosis. Furthermore, RSV further increased the AMP-activated protein kinaseα (AMPKα) phosphorylation and sirtuin1 (SIRT1) protein levels to inhibit overactivation of NF-κB pathway induced by HFD or high levels of NEFA. AMPKα or SIRT1 inhibition significantly decreased the improvement effect of RSV on the NF-κB pathway induced by high levels of NEFA. Taken together, these findings indicate that RSV supplement decreases the inflammatory level and improves hepatic steatosis through activating AMPKα-SIRT1 pathway. Therefore, these data suggested an important clinical application of RSV in preventing NAFLD in humans.
Department of Gastroenterology, The Second Hospital of Jilin University, Ziqing Road, Changchun, 130000, China.
Yueli
Y
Tian
Department of Gastroenterology, The Second Hospital of Jilin University, Ziqing Road, Changchun, 130000, China.
Jingting
J
Ma
Department of Gastroenterology, The Second Hospital of Jilin University, Ziqing Road, Changchun, 130000, China.
Wudong
W
Wang
Department of Gastroenterology, The Second Hospital of Jilin University, Ziqing Road, Changchun, 130000, China.
Lingjuan
L
Zhang
Department of Gastroenterology, The Second Hospital of Jilin University, Ziqing Road, Changchun, 130000, China.
Jia
J
Xu
Department of Gastroenterology, The Second Hospital of Jilin University, Ziqing Road, Changchun, 130000, China.
Kai
K
Wang
Department of Gastroenterology, The Second Hospital of Jilin University, Ziqing Road, Changchun, 130000, China. tyl0708@126.com.
Dongfu
D
Li
D055372:AMP-Activated Protein Kinases / Q000378:metabolism*; D000818:Animals; D016207:Cytokines / Q000096:biosynthesis; D006801:Humans; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism*; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D000077185:Resveratrol; D015398:Signal Transduction / Q000187:drug effects*; D056564:Sirtuin 1 / Q000378:metabolism*; D013267:Stilbenes / Q000494:pharmacology*
D016207:Cytokines; D016328:NF-kappa B; D013267:Stilbenes; D055372:AMP-Activated Protein Kinases; C470545:Sirt1 protein, mouse; D056564:Sirtuin 1; D000077185:Resveratrol
AMP-activated protein kinaseα; NF-κB inflammation pathway; Resveratrol; Sirtuin1